The exact PDUFA date isn’t disclosed, but it should be during Oct/Nov 2015. GT4 represents 6% of the US HCV population, but its economic relevance for ENTA is greater than the 6% figure would suggest because ENTA’s royalty rate is based on 45% of the 2-DAA regimen’s sales (rather than 30% for the 3-DAA V-Pak).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.